Jothydev's Diabetes and Research Center, Thiruvananthapuram, Kerala, India 695032.
Diabetes Technol Ther. 2009 Aug;11(8):517-21. doi: 10.1089/dia.2008.0128.
The standard treatment regimen for insulin-dependent type 2 diabetes is multiple daily injections (MDI) of insulin, but continuous subcutaneous insulin infusion (CSII) with an insulin pump offers more flexibility and the possibility of a reduced total daily insulin dose. Few studies have investigated CSII for type 2 diabetes, and none has focused on an Asian Indian population.
Subjects with type 2 diabetes who were previously using MDI were switched to CSII. Glycosylated hemoglobin (HbA1c), body weight, and total daily insulin dose were recorded at baseline (MDI) and after 6 months of CSII. Subjects were also asked to rate their satisfaction with CSII and the treatment's interference in their daily activities after 6 months.
A total of 46 subjects received CSII. Mean HbA1c was reduced by 0.5% after 6 months. This outcome was statistically significant (P < 0.0063; 95% confidence interval, 0.161-0.921%). There was no statistically significant change in body weight or total insulin daily dose. Subjects reported high satisfaction with CSII and low interference with daily activities.
Six months of CSII in Asian Indian subjects with type 2 diabetes resulted in a statistically and clinically significant change in HbA1c.
胰岛素依赖型 2 型糖尿病的标准治疗方案是多次皮下注射胰岛素（MDI），但胰岛素泵的持续皮下胰岛素输注（CSII）提供了更大的灵活性和减少总日剂量胰岛素的可能性。很少有研究调查过 CSII 在 2 型糖尿病中的应用，也没有研究专门针对亚洲印度人群。
以前使用 MDI 的 2 型糖尿病患者转换为 CSII。在基线（MDI）和 CSII 治疗 6 个月时记录糖化血红蛋白（HbA1c）、体重和总日剂量胰岛素。在 6 个月后，患者还被要求对 CSII 的满意度以及治疗对他们日常生活的干扰程度进行评分。
共有 46 名患者接受了 CSII。6 个月后，HbA1c 平均降低了 0.5%。这一结果具有统计学意义（P < 0.0063；95%置信区间，0.161-0.921%）。体重或总胰岛素日剂量没有统计学上的显著变化。患者报告对 CSII 非常满意，对日常生活干扰程度低。
6 个月的 CSII 治疗亚洲印度 2 型糖尿病患者，HbA1c 发生了统计学和临床意义上的显著变化。
